The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).

摘要: BACKGROUND Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum-gemcitabine (PG) in first-line treatment advanced non-small cell lung cancer (NSCLC) have shown inconsistent findings. This meta-analysis aimed to explore whether addition MTAs PG NSCLC could provide a survival benefit tolerable toxicity. METHODS Web knowledge, PubMed, Ovid, Embase, Cochrane Library were searched identify relevant studies extract data on overall (OS), progression-free (PFS), objective response rate (ORR), common grade 3 or 4 adverse events. Subgroup analyses conducted basis race type MTA. RESULTS Twelve trials total 6143 patients included this meta-analysis. Compared chemotherapy, combination therapy MTA did not improve OS (hazard ratio [HR] = 0.96, 95% confidence interval [CI] = 0.90-1.01) but improved PFS (HR = 0.77, CI = 0.66-0.89) ORR (risk [RR] = 1.33, CI = 1.11-1.60). Subanalysis indicated that there was more incidence rash (RR = 11.20, CI = 6.07-20.68), anemia (RR = 1.21, CI = 1.01-1.46), diarrhea (RR = 2.62, CI = 1.21-5.65), anorexia (RR = 2.08, CI = 1.12-3.88) epidermal growth factor receptor group compared group. An increased risk (RR = 5.08, CI = 1.53-16.79), thrombocytopenia (RR = 1.50, CI = 1.03-2.18), hypertension (RR = 2.36, CI = 1.05-5.32) observed sorafenib CONCLUSION The plus superior alone terms OS. chemotherapy also showed higher frequency toxic effects than chemotherapy.